2407-99-0

Usage

Uses

Used in Pharmaceutical Research:
Hexahydro-7(1H)-Indolizinone is used as a reactant in the design of novel 5-HT6 receptor antagonists for pharmaceutical research. The 5-HT6 receptor is a serotonin receptor subtype that has been implicated in various neurological and psychiatric disorders, making it an important target for drug development. The compound's structural features make it a valuable building block for the synthesis of new antagonists with potential therapeutic applications.
Used in Biological Research:
In the field of biological research, hexahydro-7(1H)-Indolizinone serves as a key intermediate for the development of new compounds with potential biological activities. Its unique structure allows for the exploration of various chemical modifications, which can lead to the discovery of novel bioactive molecules with specific targeting properties.
Used in Chemical Synthesis:
Hexahydro-7(1H)-Indolizinone is also utilized in chemical synthesis as a versatile building block for the creation of a wide range of organic compounds. Its hexahydro nature provides a stable and functionalized platform for further chemical reactions, enabling the synthesis of diverse molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 6346-09-4 4-aminobutyrylaldehyde diethylacetal 
• 78-94-4 methyl vinyl ketone 
• 194154-91-1 (+/-)-1-(tert-Butoxycarbonyl)pyrrolidine-2-acetic acid 
• 443797-18-0 tert-butyl 2-(2-(methoxy(methyl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate 
• 211310-10-0 2-(methoxy-N-methylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester 
• 98303-20-9 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid 
• 1312456-12-4 C₈H₁₃NO 
• 27132-81-6 2,4-dimethyl-penta-1,4-dien-3-one 
• 287730-08-9 1-(t-Butoxycarbonyl)-2-[4-(p-toluenesulfonyl)-2-oxobutyl]pyrrolidine 
• 443797-19-1 (+/-)-1-(t-butoxycarbonyl)-2-(2-oxo-3-butenyl)pyrrolidine 
• 74991-94-9 3-{2-[1-Ethoxycarbonyl-meth-(E)-ylidene]-pyrrolidin-1-yl}-propionic acid ethyl ester 
• 74991-93-8 ethyl 3-(2-thioxopyrrolidin-1-yl)propanoate 
• 72130-69-9 ethyl 7-oxo-1,2,3,5,6,7-hexahydroindolizine-8-carboxylate 
• 337974-50-2 8-[(tert-butoxycarbonyl)amino]-1-[(4'-methylphenyl)sulfonyl]-1-octen-3-one 

Downstream Products

• 476493-34-2 7-cyanooctahydroindolizine 
• 1428761-01-6 4-(octahydroindolizin-7-yl)aniline 
• 1428760-99-9 4-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)aniline 
• 1428761-00-5 4-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)aniline 

Relevant academic research and scientific papers

A new entry to pyrano[3,2-f]indolizines via the regioselective formation of an indolizidin-7-one enamine

From indolizidin-7-one (1), the preparation of several (pyrrolidine, piperidine and morpholine) enamines was described. The isolation of one of them (morpholine) as a pure regioisomer allowed the synthesis of pyrano[3,2-f]-indolizines for which only a few examples were known.

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to ph

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are als

NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS

The disclosure relates to a compound of formula (I): wherein R1, R2, R3, R4, R5, A and Y are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions c

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are spiro-cyclic compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metab

A two-step, formal [4 + 2] approach toward piperidin-4-ones via au catalysis

(Chemical Equation Presented) An efficient, formal [4 + 2] synthesis of synthetically valuable piperidin-4-ones from secondary amines in two steps has been achieved via a key gold catalysis without the purification of tertiary amine intermediates. This reaction is selective toward the less-substituted alkyl group and shows moderate to excellent diastereoselectivities. Its synthetic potential in alkaloid synthesis is demonstratedin a highly diastereoselective synthesis of (±)-cermizine C.

Substituted indole compounds having NOS inhibitory activity

The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination w

BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND

The present invention provides a bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines.A compound of the following formula (1): (wherein, A represents pyrrole or pyrazole, R1 represents an aryl group or a heteroaryl group which may be substituted, R2 represents a heteroaryl group which may be substituted, and R3 represents an indolizine group), or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or other pharmacologically acceptable derivative thereof.